Q2 Earnings Estimate for Cresco Labs Issued By Roth Capital

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Analysts at Roth Capital reduced their Q2 2025 earnings per share estimates for Cresco Labs in a research report issued to clients and investors on Tuesday, June 3rd. Roth Capital analyst W. Kirk now forecasts that the company will post earnings of ($0.04) per share for the quarter, down from their prior estimate of ($0.02). The consensus estimate for Cresco Labs' current full-year earnings is ($0.20) per share. Roth Capital also issued estimates for Cresco Labs' Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.13) EPS.

CRLBF has been the topic of several other research reports. Cormark raised shares of Cresco Labs from a "hold" rating to a "moderate buy" rating in a report on Monday, March 17th. Canaccord Genuity Group lowered shares of Cresco Labs from a "strong-buy" rating to a "moderate buy" rating in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy".

Cresco Labs Price Performance

CRLBF stock traded up $0.01 during trading on Thursday, hitting $0.54. The company had a trading volume of 718,874 shares, compared to its average volume of 655,730. The company has a fifty day moving average price of $0.69 and a two-hundred day moving average price of $0.84. Cresco Labs has a fifty-two week low of $0.49 and a fifty-two week high of $2.05. The company has a market cap of $265.30 million, a P/E ratio of -2.70 and a beta of 1.73. The company has a current ratio of 1.97, a quick ratio of 1.39 and a debt-to-equity ratio of 1.80.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last released its quarterly earnings data on Friday, May 30th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Cresco Labs had a negative net margin of 9.15% and a negative return on equity of 16.52%. The company had revenue of $165.76 million during the quarter, compared to the consensus estimate of $164.37 million.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.